Electronic ISSN 2287-0237

VOLUME

KRAS MUTATION TESTING IN ADVANCED COLORECTAL CANCERS

FEBRUARY 2011 - VOL.1 | REVIEWS ARTICLE
Keywords:

KRAS, Colorectal cancer, Targeted therapy,Cetuximab, Panitumumab, PCR,

MEDIA
Table 1:
Frequency of KRAS Mutations in Human Cancers
Table 2:
Impact of KRAS Mutations in Patients with Metastatic CRC Treated with EGFR
Table 3:
Common 7 KRAS mutations in exon 1 (codons 12 and 13) in CRC
Table 4:
Comparison of Methods Used for KRAS Mutation Testing
Figure 1:
KRAS testing using pyrosequencing. Pyrograms demonstrate wild-type KRAS gene (upper panel) and mutant KRAS gene (lower panel). Note a mutant “A” peak (arrow) indicating nt38 G>A (Gly13Asp, G13D) at codon 13, exon 1 of the KRAS gene. (Courtesy of Dr Chupong Ittiwut, PhD, Chulalongkorn GenePRO Center, Faculty of Medicine, Chulalongkorn University)
Figure 2:
KRAS testing using allele-specific real-time PCR (The DxS TheraScreen KRAS Mutation Kit). (A) Positive for KRAS mutation. Note the second curve (arrow) representing the amplification of a KRAS mutation. (B) Negative for KRAS mutation. Note the curve at cycle 24 (arrowhead) served as internal control (exon 4 of the KRAS gene). (C) The DxS TheraScreen KRAS Mutation Kit analysis report using the LightCycler® Adapt Software v1.1 (Roche Diagnostics, Penzberg, Germany). (Courtesy of Dr. Alisa Junpee, PhD, Bio Molecular and Pathology Laboratory, National Healthcare Systems CO., Ltd)
SEARCH VOLUME & NUMBER
GO
RECENT VOLUME & NUMBER